Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer
Although CLDN18.2 expression in PM mirrored that in primary lesions, the levels were generally reduced. When zolbetuximab is used for GC patients with peritoneal involvement, it is preferable to assess the expression of CLDN18.2 in the disseminated lesions.
Authors
- Joji Kitayama
- Shin Saito (ORCID: https://orcid.org/0000-0002-2931-4260)
- Kentaro Kurashina (ORCID: https://orcid.org/0000-0003-4034-9883)
- Hideyo Miyato
- Naohiro Sata
- Hideyuki Ohzawa (ORCID: https://orcid.org/0000-0001-9422-2840)
- Shiro Matsumoto (ORCID: https://orcid.org/0000-0003-1028-5532)
- Hironori Yamaguchi (ORCID: https://orcid.org/0000-0002-8371-9410)
- Rie Kawashima
- Akira Saito (ORCID: https://orcid.org/0000-0003-2679-3240)
- Yoshinori Hosoya
Institutions
- Jichi Medical University (JP)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/jgo-24-743
- Citations
- 4
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.37